Literature DB >> 21473138

[Expression of C-erbB-2 and EGFR expression and its relationship with cell proliferation in nasopharyngeal carcinoma].

Yan Zhang1, Gengtian Liang, Guangbin Sun, Zhaohu Pan, Guomin Wu, Zheng Liu.   

Abstract

OBJECTIVE: To study the expression of epidermal growth factor receptor (EGFR), C-erbB-2 and its relationship with cell proliferation in nasopharyngeal carcinoma.
METHOD: Expression of C-erbB-2, EGFR and proliferating cell nuclear antigen (PCNA) were detected with immunohistochemical staining in 32 nasopharyngeal carcinoma samples and 12 chronic inflammatory nasopharyngeal tissue samples. RESULT: The positive rate of EGFR,C-erbB-2, and PCNA expression in nasopharyngeal carcinoma was 65.6%, 37.5%, and (42.5 +/- 22.6)%, respectively, which was significantly higher than that in chronic inflammatory nasopharyngeal tissue (P < 0.05). There were positive correlations between the positive rate of EGFR, C-erbB-2, and PCNA expression and histopathological stage. The co-expression of C-erbB2 and EGFR was found in 62.5% (20/32) nasopharyngeal carcinoma samples. There was a positive correlation between C-erbB-2 and EGFR expression (r = 0.38, P < 0.05). The highest percentage of PCNA expression was found in carcinoma samples with co-expression of C-erbB and EGFR.
CONCLUSION: C-erbB-2, EGFR might have synergetic effect in the development and progress of nasopharyngeal carcinoma. The co-expression of C-erbB-2 and EGFR closely correlates with cell proliferation status.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21473138

Source DB:  PubMed          Journal:  Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi        ISSN: 1001-1781


  2 in total

1.  Transcriptome meta-analysis reveals dysregulated pathways in nasopharyngeal carcinoma.

Authors:  Warut Tulalamba; Noppadol Larbcharoensub; Ekaphop Sirachainan; Aunchalee Tantiwetrueangdet; Tavan Janvilisri
Journal:  Tumour Biol       Date:  2015-02-28

2.  Oncogene mutational profile in nasopharyngeal carcinoma.

Authors:  Zi-Chen Zhang; Sha Fu; Fang Wang; Hai-Yun Wang; Yi-Xin Zeng; Jian-Yong Shao
Journal:  Onco Targets Ther       Date:  2014-03-20       Impact factor: 4.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.